Trial · NCT00235755
Results by group234
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 234
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) | Placebo - Double Blind (DB) Phase (Titration Plus Maintenance) | -15.9 | Full Range -100 to 1712 | percent change in seizure frequency | |
| Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | -39.9 | Full Range -100 to 226 | percent change in seizure frequency | |
| Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance) | -27.9 | Full Range -94 to 250 | percent change in seizure frequency | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Placebo - DB Phase (Titration Plus Maintenance) | Responders | 31 | participants | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | Responders | 70 | participants | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance | Responders | 61 | participants | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Placebo - DB Phase (Titration Plus Maintenance) | Non-responders | 133 | participants | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | Non-responders | 79 | participants | |
| Number of Participants Classified as Responders and Non-responders During the Maintenance Phase | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance | Non-responders | 97 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Placebo - DB Phase (Titration Plus Maintenance) | Responders | 31 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance) | Responders | 57 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | Responders | 70 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Placebo - DB Phase (Titration Plus Maintenance) | Non-responders | 148 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance) | Non-responders | 124 | participants | |
| Number of Participants Who Were Responders and Non-responders During the DB Phase | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | Non-responders | 108 | participants | |
| Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase | Placebo - DB Phase (Titration Plus Maintenance) | -17.4 | Full Range -100 to 1589 | Percent change in seizure frequency | |
| Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance) | -35.3 | Full Range -100 to 253 | Percent change in seizure frequency | |
| Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase | Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance) | -44.3 | Full Range -100 to 714 | Percent change in seizure frequency | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Placebo - DB Phase (Titration Plus Maintenance) | 75% to 100% reduction | 12 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance) | 75% to 100% reduction | 16 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00235755/results